Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice

Neuropsychopharmacology

Volumn 21, Issue 5, 1999, Pages 670-678

  Chinen, Cibele Cristina ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Catalepsy; Conditioning; Dopamine D1 receptor; Placebo effect; Reward; SCH 23390

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; METOCLOPRAMIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LABORATORY TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REWARD; SENSITIZATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; LOCOMOTION; MALE; METOCLOPRAMIDE; MICE; MICE, INBRED STRAINS; TIME FACTORS;

EID: 0032883807     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00061-5     Document Type: Article

References (55)

1. Amir S., Brown Z.W., Amit Z., Ornstein K. Body pinch induces long lasting cataleptic like immobility in mice. Behavioral characterization and the effect of naloxone Life Sci. 28(10):1981;1189-1194.
2. Antelman S.M., Kocan D., Edwards D.J., Knopf S., Perel J.M., Stiller R. Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res. 385(1):1986;58-67.
3. Asper H., Baggiolini M., Burki H.R., Lauener H., Ruch W., Stille G. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur J Pharmacol. 22(5):1973;287-294.
4. Axelrod J., Reisine T.D. Stress hormones. Their interaction and regulation Science. 224(4648):1984;452-459.
5. Barnes D.E., Robinson B., Csernansky J.G., Bellows E.P. Sensitization versus tolerance to haloperidol-induced catalepsy. Multiple determinants Pharmacol Biochem Behav. 36(4):1990;883-887.
6. Brown J., Handley S.L. The development of catalepsy in drug-free mice on repeated testing. Neuropharmacology. 19(7):1980;675-678.
7. Campbell A., Baldessarini R.J. Tolerance to behavioral effects of haloperidol. Life Sci. 29(13):1981;1341-1346.
8. Carey R.J. Pavlovian conditioning of L-dopa induced movement. Psychopharmacology. 107(2-3):1992;203-210.
9. 1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 34(16):1984;1529-1540.
10. 1 dopamine receptor increase following chronic treatment with SCH 23390. Eur J Pharmacol. 109(1):1985;127-128.
11. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38(2):1995;95-137.
12. Dijk S., Krugers H.J., Korf J. The effect of teophylline and immobilization stress on haloperidol-induced catalepsy and on metabolism in the striatum and hippocampus, studied with lactograph. Neuropharmacology. 30(5):1991;469-473.
13. Ezrin-Waters C., Seeman P. Tolerance of haloperidol catalepsy. Eur J Pharmacol. 41(3):1977;321-327.
14. Ferré S., Guix T., Prat G., Jane F., Casas M. Is experimental catalepsy properly measured? Pharmacol Biochem Behav. 35(4):1990;753-757.
15. Frussa-Filho R., Otoboni J.R., Uema F.T., Palermo-Neto J. Effects of age and isolation on the evolution of catalepsy during chronic haloperidol treatment. Braz J Med.Biol Res. 25(9):1992;925-928.
16. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term metoclopramide administration on open-field and stereotyped behaviour of rats. Eur J Pharmacol. 149(3):1988;323-329.
17. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term administration of sulpiride on open-field and stereotyped behaviour of rats. Braz J Med Biol Res. 23(5):1990;463-472.
18. György L., Pfeifer K.A., Hajtman B. Modification of certain central nervous effects of haloperidol during long-term treatment in the mouse and rat. Psychopharmacologia (Berl). 16(3):1969;223-233.
19. Hansen TE, Hoffman WF (1997): Drug-induced Parkinsonism. In: Yassa R, Nair NPV, Jeste DV (eds). Neuroleptic-Induced Movement Disorders. New York: Cambridge University Press, pp 341-380.
20. 1 dopamine receptor up-regulation J Pharmacol Exp Ther. 238(3):1986;846-854.
21. 2 dopamine receptors J Neurosci. 8(7):1988;2361-2370.
22. Hillegaart V., Ahlenius S., Magnusson O., Fowler C.J. Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy and a conditioned avoidance response. Pharmacol Biochem Behav. 27:1987;159-164.
23. Hiroi N., White N.M. Conditioned stereotypy. behavioral specification of the UCS and pharmacological investigation of the neural change Pharmacol Biochem Behav. 32(1):1989;249-258.
24. Hoffman D.C., Beninger R.J. Conditional tolerance to haloperidol-induced catalepsy. Striatal dopamine receptor supersensitivity is a possible explanation Psychopharmacology (Berl). 95(1):1988;142-145.
25. 1 antagonist. Eur J Pharmacol. 91(1):1983;153-154.
26. 2 receptors in the nucleus accumbens in mediating reward. J Neurosci. 17(21):1997;8580-8587.
27. Iwata S., Izumi K., Shimizu T., Fukuda T. Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice. Pharmacol Biochem Behav. 33(3):1989;705-707.
28. Lipska B.K., Jaskiw G.E., Braun A.R., Weinberger D.R. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatry. 38:1995;255-262.
29. Kinon B.J., Kane J.M. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. Psychopharmacology (Berl). 98(4):1989;465-471.
30. Klemm W.R. The catalepsy of blocked dopaminergic receptors. Psychopharmacology (Berl). 111(2):1993;251-253.
31. Lappalainen J., Hietala J., Syvälahti E. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology (Berl). 98(4):1989;472-475.
32. Lynch J.J., Stein E.A., Fertziger A.P. An analysis of 70 years of morphine classical conditioning. Implications for clinical treatment of narcotic addiction J Nerv Mental Disease. 163(1):1976;47-58.
33. 1 receptor as a primary site of therapeutic action of neuroleptic drugs Progr Neurobiol. 34(2):1990;143-183.
34. Mizuki Y., Ushijima I., Yamada M. Effects of chronic methamphetamine on SCH 23390- or haloperidol- induced catalepsy, and effects of coadministration of SCH 23390 or haloperidol in mice. Pharmacol Biochem Behav. 53(2):1996;437-440.
35. Moller Nielsen I., Fjalland B., Pedersen V., Nymark M. Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia (Berl). 34(2):1974;95-104.
36. 1 antagonist SCH 23390. Psychopharmacology. 82(4):1984;409-410.
37. 2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology. 102(3):1990;411-413.
38. Pavlov I.P. Conditioned Reflexes. 1927;Oxford University Press, London.
39. Pickens R.W., Crowder W.F. Effects of CS-US interval on conditioning of drug response, with assessment of speed of conditioning. Psychopharmacologia. 11(1):1967;88-94.
40. Rocha J.B., Santos J.E., Rocha L.K., Kleinpaul E.R. Undernutrition during suckling changes the sensitivity to haloperidol and chlorpromazine in two behavioural measures in weaning rats. Pharmacol Toxicol. 81(3):1997;114-123.
41. Sanberg P.R. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature. 284(5755):1980;472-473.
42. Sanberg P.R., Bunsey M.D., Giordano M., Norman A.B. The catalepsy test. its ups and downs Behav Neurosci. 102:1988;748-759.
43. Schiff S.R., Bridger W.H., Sharless N.S., King J.J. Conditioning using drugs affecting dopaminergic systems as unconditioned stimuli. Behavioral and biochemical evidence Psychopharmacol Bull. 16:1980;24-27.
44. Schiff S.R. Conditioned dopaminergic activity. Biol Psychiatry. 17(2):1982;135-155.
45. Seeman P. Brain dopamine receptors. Pharmacol Rev. 32:1980;229-313.
46. St. Jean A., Donald M.W., Ban T.A. Uses and abuses of antiparkinsonian medication. Am J Psychiatry. 120:1964;801-803. a.
47. St. Jean A., Donald M., Ban T.A. Interchangeability of Antiparkinsonian medication. Am J Psychiatry. 120:1964;1189-1190. b.
48. Stanley M.E., Glick S.D. Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology. 15(7):1976;393-394.
49. Suchman A.L., Ader R. Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther. 52(4):1992;372-377.
50. Tilson H.A., Rech R.H. Conditioned drug effects and absence of tolerance to d-amphetamine induced motor activity. Pharmacol Biochem Behav. 1:1973;149-153.
51. Undie AS, Friedman E (1988): Differences in the cataleptogenic actions of SCH 23390 and selected classical neuroleptics. Psychopharmacology 96:311-316.
52. Ushijima I., Mizuki Y., Yamada M. Development of tolerance and reverse tolerance to haloperidol- and SCH 23390-induced cataleptic effects during withdrawal periods after long-term treatment. Pharmacol Bioch Behav. 50(2):1995;259-264.
53. Vital M.A.B.F., Frussa-Filho R., Palermo-Neto J. Effects of monosialoganglioside on dopaminergic supersensitivity. Life Sci. 56(26):1995;2299-2307.
54. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Reviews. 94:1987;469-492.
55. Wise R.A., Rompre P.-P. Brain dopamine and reward. Annu Rev Psychol. 40:1989;191-225.